pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 8·1 min read
save

Odyssey raises more than $300M as biotech goes public

Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The biotech sold 15.5 million shares {$ODTX} at ...

May 8, 2026·read at Endpoints ↗

May 7, 2026 09:44 PM EDT FinancingStartupsIPOs Odyssey rais­es more than $300M as biotech goes pub­lic in IPO Kyle LaHucik Biotech Correspondent Odyssey Ther­a­peu­tics pulled to­geth­er $279 mil­lion from its ini­tial pub­lic of­fer­ing, the au­toim­mune dis­ease drug de­vel­op­er said Thurs­day night. With its IPO now priced, Odyssey … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
82 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Immunology

related stories

  • Apr 29AbbVie faces questions about Skyrizi competition from J&JEndpoints
  • Apr 29Teva nabs experimental Tourette drug in $700M Emalex buyoutBioPharma Dive
  • Apr 28Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug developmentSTAT
  • Apr 28FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsBioPharma Dive
  • Apr 28Coultreon banks $125M to support testing of former Galapagos immune drugBioPharma Dive